Silk Protein Technology for biologic stabilization

Vaxess Technologies is pioneering a transformative approach to the delivery of vaccines and therapeutics through its innovative MIMIX™ platform. This platform utilizes a proprietary transdermal patch that features dissolvable microarray tips made from advanced biomaterials, allowing for the controlled and gradual release of bioactive compounds directly into the skin's immunologically active dermal barrier. The MIMIX™ patch is designed to be needle-free and virtually painless, resembling an adhesive bandage, which enhances user experience and accessibility. Importantly, the technology does not require refrigeration, making it suitable for distribution in low-resource settings and enabling self-administration in various environments, including at home.

The MIMIX™ platform stands out for its versatility and consistency in delivering a wide range of vaccines and biologics, including next-generation mRNA vaccines and therapies like GLP-1. Its design allows for flexible array sizes and optimized distribution, eliminating the need for cold chain logistics and facilitating easier access to essential healthcare solutions. Vaxess aims to dismantle barriers associated with traditional vaccination methods, thereby improving the overall effectiveness, tolerability, and accessibility of medical treatments for diverse populations worldwide.

United States

Vaxess Technologies is a venture capital and Gates Foundation-backed life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk  platform.  We are committed to improving access to vaccines by enabling better, more stable vaccine products that can be easily delivered all over the world. 
Find more information at www.vaxess.com.

Vaxess Technologies

Company Details